Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte announces the presentation of four abstracts at the CHEST 2021 Annual Meeting, highlighting the clinical impact of its genomic diagnostic tests for lung cancer. The studies show that the Percepta Nasal Swab test can effectively assess cancer risk in patients with lung nodules, enhancing decision-making for treatment options. Additional findings reinforce the value of the Percepta GSC and Envisia GC in managing lung cancer and interstitial lung disease.
Veracyte (Nasdaq: VCYT) announced that its Decipher® Prostate RP genomic classifier is included in the 2022 NCCN Clinical Practice Guidelines for Oncology, advocating its use for treatment decisions in prostate cancer. The guidelines recommend Decipher Prostate RP for patients post-radical prostatectomy, particularly for those with high-risk scores (>0.6) for salvage radiotherapy. This recognition stems from data showing the classifier's predictive value in clinical outcomes, including survival rates and response to hormone therapy.
Veracyte, Inc. (NASDAQ: VCYT) has appointed Dr. Joshua Klopper as its new medical director of Endocrinology. Dr. Klopper, a distinguished endocrinologist with expertise in thyroid nodules and cancer, previously served at the Colorado Permanente Medical Group. His clinical research experience includes significant contributions to the Afirma genomic classifier, supporting Veracyte’s mission to enhance patient outcomes through genomic diagnostics. This leadership addition aims to strengthen Veracyte's capabilities in thyroid health management.
Veracyte, Inc. (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14 at 3:30 p.m. Eastern Time. A live audio webcast of the event will be available on Veracyte's website, with replays accessible for 90 days post-event. Veracyte is dedicated to enhancing patient care through innovative genomic tests for various cancers and diseases, helping avoid unnecessary procedures and expediting treatment.
Summary not available.
Veracyte, Inc (Nasdaq: VCYT) has successfully completed its acquisition of HalioDx for €260 million, consisting of €147 million in cash and €113 million in stock. This strategic move aims to enhance Veracyte's reach in global markets and expand its diagnostic capabilities into eight of the ten most prevalent cancers in the U.S. CEO Marc Stapley highlighted that HalioDx's European manufacturing and immuno-oncology expertise could significantly drive revenue growth in cancer diagnostics. Bonnie Anderson will oversee the integration of operations in France.
Veracyte, Inc. (Nasdaq: VCYT) reported a robust second quarter of 2021, with total revenue reaching $55.1 million, a 166% increase year-over-year. The gross margin improved to 68%, reflecting a positive trend in operational efficiency. Despite a $9.0 million net loss, there was an 18% improvement compared to the previous year. Notably, the company enhanced its revenue guidance for the full year to $200 million - $208 million, indicating a revised growth rate of 69% to 76% over 2020. Key strategic moves include the anticipated acquisition of HalioDx to bolster growth in cancer diagnostics.
Veracyte (Nasdaq: VCYT) announced promising data regarding its Decipher Prostate Biopsy genomic classifier, which may assist in treatment decisions for prostate cancer patients eligible for active surveillance. A retrospective analysis from the MUSIC registry revealed that high Decipher scores predict quicker transitions from active surveillance to definitive treatment and increased treatment failure rates. The study included 855 participants and found significant differences in treatment timelines based on Decipher scores. The ongoing investigation includes numerous clinical trials to further validate these findings.
Veracyte, Inc. (Nasdaq: VCYT) has appointed Rebecca Chambers as its new executive vice president and chief financial officer, effective July 19. Chambers brings extensive healthcare leadership experience, previously serving as CFO at Outset Medical and holding key financial roles at Illumina. CEO Marc Stapley expressed confidence in Chambers' ability to enhance the company’s financial operations and support its growth strategy. Veracyte focuses on genomic diagnostics to improve patient care and has a portfolio of tests for various cancers. The company aims to drive growth through innovative strategies and international expansion.
Veracyte (Nasdaq: VCYT) announced it will release its Q2 2021 financial results after the market closes on July 29. A conference call and webcast will be held at 4:30 p.m. ET on the same day to discuss these results and provide a business update. Participants can access the call through designated dial-in numbers, with a replay available on the company’s website. Veracyte specializes in genomic diagnostics, providing tests for various cancers and diseases, aiming to improve patient care and reduce unnecessary procedures.